{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T03:29:52Z","timestamp":1794799792661,"version":"4.9.1"},"reference-count":58,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T00:00:00Z","timestamp":1694131200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","award":["CA180190"],"award-info":[{"award-number":["CA180190"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015220","name":"University of Arkansas for Medical Sciences Winthrop P Rockefeller Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015220","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA151354"],"award-info":[{"award-number":["R01 CA151354"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA234181"],"award-info":[{"award-number":["R01 CA234181"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U54CA272691-01"],"award-info":[{"award-number":["U54CA272691-01"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["3R01-CA236814-03S1"],"award-info":[{"award-number":["3R01-CA236814-03S1"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015515","name":"Roy J. and Lucille A. Carver College of Medicine, University of Iowa","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015515","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018866","name":"Paula and Rodger Riney Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018866","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015317","name":"University of Arkansas for Medical Sciences Center for Translational Neuroscience","doi-asserted-by":"publisher","award":["KL2 TR003108"],"award-info":[{"award-number":["KL2 TR003108"]}],"id":[{"id":"10.13039\/100015317","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020492","name":"Translational Research Institute Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008519","name":"University of Arkansas for Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008519","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001253","name":"Multiple Myeloma Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001253","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008169","name":"Minneapolis Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008169","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.xcrm.2023.101214","type":"journal-article","created":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T10:37:00Z","timestamp":1696329420000},"page":"101214","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["High NEK2 expression in myeloid progenitors suppresses T\u00a0cell immunity in multiple myeloma"],"prefix":"10.1016","volume":"4","author":[{"given":"Yan","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumou","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisy V.","family":"Alapat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Visanu","family":"Wanchai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Mery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wancheng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huojun","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cody","family":"Ashby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Anton","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Intawat","family":"Nookaew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric R.","family":"Siegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Ran","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongzheng","family":"Gai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bailu","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clyde","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samer","family":"Al Hadidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Schinke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharmilan","family":"Thanendrarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Zangari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Chesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Leif","family":"Bergsagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frits","family":"van Rhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siegfried","family":"Janz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Tricot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"John D.","family":"Shaughnessy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5417-2973","authenticated-orcid":false,"given":"Fenghuang","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2023.101214_bib1","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.xcrm.2023.101214_bib2","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1182\/blood.V98.4.934","article-title":"T-cell--depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect","volume":"98","author":"Alyea","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2023.101214_bib3","doi-asserted-by":"crossref","first-page":"4206","DOI":"10.1182\/blood.V90.10.4206","article-title":"Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation","volume":"90","author":"Lokhorst","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2023.101214_bib4","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1182\/blood.V87.3.1196.bloodjournal8731196","article-title":"Graft-versus-myeloma effect: proof of principle","volume":"87","author":"Tricot","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2023.101214_bib5","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1111\/cas.15556","article-title":"Ciltacabtagene autoleucel in patients with relapsed\/refractory multiple myeloma: CARTITUDE-1 (phase 2) Japanese cohort","volume":"113","author":"Ri","year":"2022","journal-title":"Cancer Sci."},{"key":"10.1016\/j.xcrm.2023.101214_bib6","doi-asserted-by":"crossref","first-page":"e897","DOI":"10.1016\/S2352-3026(22)00284-8","article-title":"Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label study","volume":"9","author":"Martin","year":"2022","journal-title":"Lancet. Haematol."},{"key":"10.1016\/j.xcrm.2023.101214_bib7","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13045-022-01301-8","article-title":"Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2)","volume":"15","author":"Zhao","year":"2022","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.xcrm.2023.101214_bib8","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.clml.2022.10.001","article-title":"Patient Perceptions Regarding Ciltacabtagene Autoleucel Treatment: Qualitative Evidence From Interviews With Patients With Relapsed\/Refractory Multiple Myeloma in the CARTITUDE-1 Study","volume":"23","author":"Cohen","year":"2023","journal-title":"Clin. Lymphoma, Myeloma\u00a0& Leukemia"},{"key":"10.1016\/j.xcrm.2023.101214_bib9","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13045-016-0345-3","article-title":"T cells in multiple myeloma display features of exhaustion and senescence at the tumor site","volume":"9","author":"Zelle-Rieser","year":"2016","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.xcrm.2023.101214_bib10","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1158\/2643-3230.BCD-22-0018","article-title":"Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in Myeloma","volume":"3","author":"Dhodapkar","year":"2022","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.xcrm.2023.101214_bib11","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1182\/blood-2018-01-825265","article-title":"TIGIT immune checkpoint blockade restores CD8(+) T-cell immunity against multiple myeloma","volume":"132","author":"Guillerey","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2023.101214_bib12","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/nri3740","article-title":"T cell differentiation in chronic infection and cancer: functional adaptation or exhaustion?","volume":"14","author":"Speiser","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.xcrm.2023.101214_bib13","doi-asserted-by":"crossref","first-page":"6960","DOI":"10.1038\/s41467-021-26951-z","article-title":"Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single-cell transcriptomics","volume":"12","author":"Tirier","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2023.101214_bib14","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.ccell.2018.02.007","article-title":"Dysregulated IL-18 Is a Key Driver of Immunosuppression and a Possible Therapeutic Target in the Multiple Myeloma Microenvironment","volume":"33","author":"Nakamura","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2023.101214_bib15","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1016\/j.immuni.2021.07.002","article-title":"beta(2)-microglobulin triggers NLRP3 inflammasome activation in tumor-associated macrophages to promote multiple myeloma progression","volume":"54","author":"Hofbauer","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.xcrm.2023.101214_bib16","article-title":"Tumor-associated macrophages in multiple myeloma: advances in biology and therapy","volume":"10","author":"Sun","year":"2022","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2023.101214_bib17","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41419-021-03748-y","article-title":"BMI1 regulates multiple myeloma-associated macrophage's pro-myeloma functions","volume":"12","author":"Zhang","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.xcrm.2023.101214_bib18","doi-asserted-by":"crossref","DOI":"10.1172\/JCI145296","article-title":"Breast cancer-derived GM-CSF regulates arginase 1 in myeloid cells to promote an immunosuppressive microenvironment","volume":"131","author":"Su","year":"2021","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.xcrm.2023.101214_bib19","first-page":"1336","article-title":"Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcgammaR engagement and type I interferon signaling","volume":"3","author":"Yofe","year":"2022","journal-title":"Nat. Can. (Ott.)"},{"key":"10.1016\/j.xcrm.2023.101214_bib20","doi-asserted-by":"crossref","DOI":"10.1172\/JCI157907","article-title":"TIGIT inhibition and lenalidomide synergistically promote anti-myeloma immune responses after stem cell transplantation in mice","volume":"133","author":"Minnie","year":"2023","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.xcrm.2023.101214_bib21","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ccr.2012.12.001","article-title":"NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers","volume":"23","author":"Zhou","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2023.101214_bib22","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1172\/JCI98765","article-title":"Destabilizing NEK2 overcomes resistance to proteasome inhibition in multiple myeloma","volume":"128","author":"Franqui-Machin","year":"2018","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.xcrm.2023.101214_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25081778","article-title":"Checking NEKs: Overcoming a Bottleneck in Human Diseases","volume":"25","author":"Peres de Oliveira","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.xcrm.2023.101214_bib24","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/621082","article-title":"Nek2 is a novel regulator of B cell development and immunological response","volume":"2014","author":"Gu","year":"2014","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.xcrm.2023.101214_bib25","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.1038\/s41467-021-24769-3","article-title":"NEK2 inhibition triggers anti-pancreatic cancer immunity by targeting PD-L1","volume":"12","author":"Zhang","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2023.101214_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27020347","article-title":"Nek2 Kinase Signaling in Malaria, Bone, Immune and Kidney Disorders to Metastatic Cancers and Drug Resistance: Progress on Nek2 Inhibitor Development","volume":"27","author":"Dana","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.xcrm.2023.101214_bib27","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1158\/1078-0432.CCR-19-1868","article-title":"Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade","volume":"26","author":"House","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2023.101214_bib28","doi-asserted-by":"crossref","first-page":"7040","DOI":"10.1038\/s41467-022-33944-z","article-title":"Single cell characterization of myeloma and its precursor conditions reveals transcriptional signatures of early tumorigenesis","volume":"13","author":"Boiarsky","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2023.101214_bib29","doi-asserted-by":"crossref","DOI":"10.1172\/JCI159527","article-title":"CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation","volume":"132","author":"Gai","year":"2022","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.xcrm.2023.101214_bib30","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1186\/1471-2407-14-630","article-title":"Macrophage migration inhibitory factor engages PI3K\/Akt signalling and is a prognostic factor in metastatic melanoma","volume":"14","author":"Oliveira","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.xcrm.2023.101214_bib31","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s12276-022-00736-w","article-title":"The mechanism of HMGB1 secretion and release","volume":"54","author":"Chen","year":"2022","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.xcrm.2023.101214_bib32","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","article-title":"The molecular classification of multiple myeloma","volume":"108","author":"Zhan","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2023.101214_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003323","article-title":"Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials","volume":"17","author":"Danziger","year":"2020","journal-title":"PLoS Med."},{"key":"10.1016\/j.xcrm.2023.101214_bib34","article-title":"PD-L1\/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients","volume":"11","author":"Costa","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2023.101214_bib35","doi-asserted-by":"crossref","first-page":"920","DOI":"10.3109\/10428191003699563","article-title":"Dysregulation in T helper 1\/T helper 2 cytokine ratios in patients with multiple myeloma","volume":"51","author":"Sharma","year":"2010","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.xcrm.2023.101214_bib36","doi-asserted-by":"crossref","first-page":"e511","DOI":"10.1038\/bcj.2016.118","article-title":"A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival","volume":"6","author":"Botta","year":"2016","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.xcrm.2023.101214_bib37","doi-asserted-by":"crossref","first-page":"5873","DOI":"10.1182\/bloodadvances.2022007217","article-title":"Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level","volume":"6","author":"Schinke","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.xcrm.2023.101214_bib38","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/s41375-021-01422-y","article-title":"Transient regulatory T-cell targeting triggers immune control of multiple myeloma and prevents disease progression","volume":"36","author":"Dahlhoff","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.xcrm.2023.101214_bib39","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2023.101214_bib40","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/10428194.2017.1320713","article-title":"Efficacy and toxicity of therapy immediately after treatment with nivolumab in relapsed multiple myeloma","volume":"59","author":"Pianko","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.xcrm.2023.101214_bib41","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2023.101214_bib42","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1182\/blood-2017-03-775122","article-title":"Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed\/refractory multiple myeloma","volume":"130","author":"Badros","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2023.101214_bib43","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1111\/bjh.15946","article-title":"Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study","volume":"186","author":"Mateos","year":"2019","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.xcrm.2023.101214_bib44","doi-asserted-by":"crossref","first-page":"e459","DOI":"10.1016\/S2352-3026(19)30110-3","article-title":"Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial","volume":"6","author":"Mateos","year":"2019","journal-title":"Lancet. Haematol."},{"key":"10.1016\/j.xcrm.2023.101214_bib45","doi-asserted-by":"crossref","first-page":"TPS8052","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS8052","article-title":"CheckMate 602: An open-label, randomized, phase 3 trial of combinations of nivolumab, elotuzumab, pomalidomide and dexamethasone in relapsed\/refractory multiple myeloma","volume":"35","author":"Lonial","year":"2017","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2023.101214_bib46","doi-asserted-by":"crossref","first-page":"e448","DOI":"10.1016\/S2352-3026(19)30109-7","article-title":"Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial","volume":"6","author":"Usmani","year":"2019","journal-title":"Lancet. Haematol."},{"key":"10.1016\/j.xcrm.2023.101214_bib47","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2006-10-051482","article-title":"Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-TRAF6-and MEK-dependent pathway","volume":"110","author":"Liu","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2023.101214_bib48","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.18632\/oncotarget.26726","article-title":"PD-L1 upregulation in myeloma cells by panobinostat in combination with interferon-gamma","volume":"10","author":"Iwasa","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.xcrm.2023.101214_bib49","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1158\/1078-0432.CCR-22-0015","article-title":"Microenvironment Is a Key Determinant of Immune Checkpoint Inhibitor Response","volume":"28","author":"Cho","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2023.101214_bib50","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1158\/1078-0432.CCR-21-3329","article-title":"Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types","volume":"28","author":"Cristescu","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2023.101214_bib51","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/leu.2012.213","article-title":"Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma","volume":"27","author":"Tamura","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.xcrm.2023.101214_bib52","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ccell.2020.02.006","article-title":"ADORA1 Inhibition Promotes Tumor Immune Evasion by Regulating the ATF3-PD-L1 Axis","volume":"37","author":"Liu","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2023.101214_bib53","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S8756-3282(97)00056-2","article-title":"A murine model of human myeloma bone disease","volume":"20","author":"Garrett","year":"1997","journal-title":"Bone"},{"key":"10.1016\/j.xcrm.2023.101214_bib54","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1182\/blood-2012-02-412783","article-title":"Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy","volume":"120","author":"Chesi","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2023.101214_bib55","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/j.cell.2019.05.031","article-title":"Comprehensive Integration of Single-Cell Data","volume":"177","author":"Stuart","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2023.101214_bib56","doi-asserted-by":"crossref","DOI":"10.1103\/PhysRevE.83.036103","article-title":"Unfolding communities in large complex networks: combining defensive and offensive label propagation for core extraction","volume":"83","author":"Subelj","year":"2011","journal-title":"Phys. Rev. E - Stat. Nonlinear Soft Matter Phys."},{"key":"10.1016\/j.xcrm.2023.101214_bib57","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/s13059-015-0844-5","article-title":"MAST: a flexible statistical framework for assessing transcriptional changes and characterizing heterogeneity in single-cell RNA sequencing data","volume":"16","author":"Finak","year":"2015","journal-title":"Genome Biol."},{"key":"10.1016\/j.xcrm.2023.101214_bib58","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/cyto.a.23926","article-title":"Automated Data Cleanup for Mass Cytometry","volume":"97","author":"Bagwell","year":"2020","journal-title":"Cytometry A."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379123003816?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379123003816?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T08:15:20Z","timestamp":1778919320000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379123003816"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":58,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S2666379123003816"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2023.101214","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High NEK2 expression in myeloid progenitors suppresses T\u00a0cell immunity in multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2023.101214","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors.","name":"copyright","label":"Copyright"}],"article-number":"101214"}}